Search results for "Modality"

showing 10 items of 651 documents

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency

2016

BACKGROUND: The consensus documents published to date on hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) have focused on adult patients. Many of the previous recommendations have not been adapted to pediatric patients. We intended to produce consensus recommendations for the diagnosis and management of pediatric patients with C1-INH-HAE.METHODS: During an expert panel meeting that took place during the 9th C1 Inhibitor Deficiency Workshop in Budapest, 2015 (www.haenet.hu), pediatric data were presented and discussed and a consensus was developed by voting.RESULTS: The symptoms of C1-INH-HAE often present in childhood. Differential diagnosis can be difficult as abdominal pain…

MaleAbdominal painPediatricsdiagnosisComorbidityDiseaseSeverity of Illness IndexEcallantide0302 clinical medicineRisk FactorsDiagnosisImmunology and Allergyheterocyclic compounds030212 general & internal medicineHereditary angioedemaPediatricHereditary Angioedema Types I and IIAge FactorsDisease ManagementCombined Modality TherapyImmunodeficienciesManagementHereditary angioedemaFemaleOriginal ArticleSymptom Assessmentmedicine.symptommanagementAlgorithmsmedicine.drugmedicine.medical_specialtyC1 inhibitor deficiencyImmunology03 medical and health sciencesMeta-Analysis as TopicmedicineHumansMucous MembraneAdult patientsbusiness.industryOriginal ArticlesC1 inhibitor deficiency; Diagnosis; Hereditary angioedema; Management; Pediatric; Immunology and Allergy; Immunologybacterial infections and mycosesmedicine.diseasehereditary angioedemarespiratory tract diseasesClinical trialpediatric030228 respiratory systemC1 inhibitor deficiencyDifferential diagnosisbusinessBiomarkers
researchProduct

Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.

2016

Background Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and bone strength. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to progressive muscle degeneration and also high incidence of fractures. The aim of our study was to test whether inhibition of activin receptor IIB ligands with or without exercise could improve bone strength in the mdx mouse model for DMD. Methods Thirty-two mdx mice were divided to running and non-running groups and to receive either PBS control or soluble activin type IIB-receptor (ActRIIB-Fc) once weekly for 7 weeks. Results Treatment of mdx mice with ActRIIB-Fc resulted in significantly in…

MaleActivin Receptors Type IIDrug Evaluation PreclinicalOsteoclastsBone μCTBone and BonesMiceTGF-βsBone DensityPhysical Conditioning AnimalAnimalsBone ResorptionMuscle SkeletalExerciseOsteoblastsOrgan SizeMuscular Dystrophy AnimalCombined Modality TherapyBone-muscle interactionsAnimal modelsMice Inbred C57BLMuscular Dystrophy DuchenneDisease Models AnimalSolubilityMice Inbred mdxResearch ArticleBMC musculoskeletal disorders
researchProduct

Soft tissue Ewing sarcoma--peripheral primitive neuroectodermal tumor with atypical clear cell pattern shows a new type of EWS-FEV fusion transcript.

2000

This study describes a new case of Ewing sarcoma (ES)-peripheral primitive neuroectodermal tumor (pPNET) with unusual phenotype and fusion gene structure. The tumor located in the inguinal area of a 15-year-old boy showed a highly aggressive behavior with hematogenous metastases after intensive chemotherapy and bone marrow transplant, causing death 28 months after diagnosis. The tumor displayed a clear cell pattern, and several neuroectodermal markers proved positive both in the original tumor and in xenografts. This neuroectodermal character was confirmed by electron microscopy. Moreover, cytogenetically the tumor has an unusual chromosomal rearrangement, t(2;22)(q13;q22,t(3;18)(p21;q23); …

MaleAdolescentOncogene Proteins FusionChromosomes Human Pair 22Transplantation HeterologousMice NudeSoft Tissue NeoplasmsChromosomal rearrangementSarcoma EwingBiologyGroinTranslocation GeneticPathology and Forensic MedicineFusion geneExonMiceFatal OutcomemedicineTumor Cells CulturedAnimalsHumansNeuroectodermal Tumors PrimitiveNeoplasm MetastasisMolecular BiologyPeripheral Primitive Neuroectodermal TumorReverse Transcriptase Polymerase Chain ReactionCell BiologyExonsmedicine.diseasePrognosisCombined Modality TherapyNeoplasm ProteinsFusion transcriptPrimitive neuroectodermal tumorChromosomes Human Pair 2KaryotypingCancer researchDisease ProgressionSarcomaClear cellDiagnostic molecular pathology : the American journal of surgical pathology, part B
researchProduct

Multisensory integration in hemianopia and unilateral spatial neglect: Evidence from the sound induced flash illusion.

2016

Recent neuropsychological evidence suggests that acquired brain lesions can, in some instances, abolish the ability to integrate inputs from different sensory modalities, disrupting multisensory perception. We explored the ability to perceive multisensory events, in particular the integrity of audio-visual processing in the temporal domain, in brain-damaged patients with visual field defects (VFD), or with unilateral spatial neglect (USN), by assessing their sensitivity to the 'Sound-Induced Flash Illusion' (SIFI). The study yielded two key findings. Firstly, the 'fission' illusion (namely, seeing multiple flashes when a single flash is paired with multiple sounds) is reduced in both left- …

MaleAgingVisual perceptiongenetic structuresSound-induced flash illusionNeuropsychological TestsFunctional LateralityBehavioral Neuroscience0302 clinical medicineAttentionmedia_commonAged 80 and overVisual field defect05 social sciencesBrainMiddle AgedIllusionsVisual fieldIllusionCerebrovascular DisorderAuditory PerceptionVisual PerceptionNeuropsychological TestFemalePerceptual DisordersPerceptual DisorderPsychologyHumanCognitive psychologyAuditory perceptionAdultCognitive Neurosciencemedia_common.quotation_subjectIllusionExperimental and Cognitive Psychology050105 experimental psychologyPerceptual Disorders03 medical and health sciencesStimulus modalityPerceptionHumans0501 psychology and cognitive sciencesNeglectAgedMultisensory perceptionMultisensory integrationTemporal processingCerebrovascular DisordersAcoustic StimulationSpace Perception030217 neurology & neurosurgeryPhotic StimulationNeuropsychologia
researchProduct

The Size of Subconjunctival Preparation Does Not Influence the Outcome of Trabeculectomy With Mitomycin C

2014

PURPOSE To compare the outcome of fornix-based trabeculectomy with mitomycin C (MMC) using 2 different sizes of subconjunctival preparation (36 mm² compared with 72 mm²). METHODS Prospective, randomized interventional case series. STUDY POPULATION Patients 18 to 85 years of age with open-angle glaucoma and progressive visual field defects under maximum tolerated medical therapy were randomized to undergo initial fornix-based trabeculectomy with MMC (0.2 mg/mL for 5 min) with subconjunctival preparation of 6×6 mm (group A) or 8×9 mm (group B). Main outcome parameters were: intraocular pressure (IOP), best-corrected visual acuity (BCVA), number of 5-fluorouracil (5-FU) injections, and laser s…

MaleAlkylating Agentsmedicine.medical_specialtyIntraocular pressureVisual acuitygenetic structuresMitomycinmedicine.medical_treatmentVisual AcuityGlaucomaTrabeculectomyGroup BTonometry OcularPostoperative ComplicationsOphthalmologymedicineHumansTrabeculectomyProspective StudiesIntraocular PressureAgedAged 80 and overGlaucoma medicationbusiness.industryMitomycin CMiddle Agedmedicine.diseaseCombined Modality Therapyeye diseasesOphthalmologyTreatment OutcomePopulation studyFemaleFluorouracilsense organsmedicine.symptombusinessConjunctivaGlaucoma Open-AngleFollow-Up StudiesJournal of Glaucoma
researchProduct

Is PRP useful in alveolar cleft reconstruction? Platelet-rich plasma in secondary alveoloplasty

2009

Objective: Cleft lip and palate is a congenital facial malformation with an established treatment protocol. Mixed dentition period is the best moment for correct maxillary bone defect with an alveoloplasty. The aim of this surgical procedure is to facilitate dental eruption, re-establish maxillary arch, close any oro-nasal communication, give support to nasal ala, and in some cases allow dental rehabilitation with osteointegrated implants. Study design: Twenty cleft patients who underwent secondary alveoloplasty were included. In 10 of them autogenous bone graft were used and in other 10 autogenous bone and platelet-rich plasma (PRP) obtained from autogenous blood. Bone formation was compar…

MaleBone RegenerationCleft LipDentistryAlveoloplastyMedicineHumansBone formationMixed dentitionBone regenerationChildGeneral DentistryMaxillary archBone Transplantationbusiness.industryPlatelet-Rich PlasmaAlveoloplasty:CIENCIAS MÉDICAS [UNESCO]Combined Modality TherapyNasal alaCleft PalateOtorhinolaryngologyPlatelet-rich plasmaDental eruptionUNESCO::CIENCIAS MÉDICASSurgeryFemalebusiness
researchProduct

Gaming is related to enhanced working memory performance and task-related cortical activity

2017

Gaming experience has been suggested to lead to performance enhancements in a wide variety of working memory tasks. Previous studies have, however, mostly focused on adult expert gamers and have not included measurements of both behavioral performance and brain activity. In the current study, 167 adolescents and young adults (aged 13–24 years) with different amounts of gaming experience performed an n-back working memory task with vowels, with the sensory modality of the vowel stream switching between audition and vision at random intervals. We studied the relationship between self-reported daily gaming activity, working memory (n-back) task performance and related brain activity measured u…

MaleBrain activity and meditationNeuropsychological TestsTask (project management)Developmental psychologyCohort StudiesCreativity0302 clinical medicineSurveys and Questionnairesgaming10. No inequalityta515Cerebral CortexBrain Mappingdorsolateral prefrontal cortexmedicine.diagnostic_testGeneral Neuroscience05 social sciencesSMA*Magnetic Resonance ImagingMemory Short-Termmedicine.anatomical_structurefunctional MRIFemalePsychologypsychological phenomena and processesCognitive psychologyAdolescent515 Psychologyeducationta3112behavioral disciplines and activitiesworking memory050105 experimental psychologyYoung Adult03 medical and health sciencesStimulus modalitymedicineHumans0501 psychology and cognitive sciencesAssociation (psychology)Molecular BiologyAnalysis of VarianceInternetWorking memorytyömuistiDorsolateral prefrontal cortexCross-Sectional StudiesVideo Gamesadolescence516 Educational sciencesSelf ReportNeurology (clinical)Functional magnetic resonance imaginghuman activities030217 neurology & neurosurgeryDevelopmental Biology
researchProduct

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone ly…

2015

Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%).…

MaleCancer ResearchBiopsymedicine.medical_treatmentfirst lineKaplan-Meier EstimateSplenic marginal zone lymphoma; first line; rituximabPolyethylene GlycolGastroenterologyPolyethylene GlycolsrituximabBone MarrowPrednisonefirst line; rituximab; splenic marginal zone lymphomaCause of DeathAntineoplastic Combined Chemotherapy ProtocolsSplenic marginal zone lymphomaAged 80 and overHematologyMiddle AgedPrognosisCombined Modality TherapySplenic NeoplasmTreatment OutcomeItalyOncologyVincristineFemaleRituximabHumanmedicine.drugAdultmedicine.medical_specialtyVincristineLymphoma B-CellCyclophosphamidePrognosiSplenectomySplenic NeoplasmNeutropeniaImmunophenotypingfirst line; rituximab; Splenic marginal zone lymphoma; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Italy; Kaplan-Meier Estimate; Lymphoma B-Cell; Male; Middle Aged; Polyethylene Glycols; Prednisone; Prognosis; Rituximab; Splenic Neoplasms; Treatment Outcome; Vincristine; Hematology; Oncology; Cancer ResearchInternal medicinemedicineHumansSplenic marginal zone lymphomaCyclophosphamideAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industrySplenic NeoplasmsBiomarkermedicine.diseaseSurgeryDoxorubicinPrednisonebusinessBiomarkers
researchProduct

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

2013

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. Methods The study presented was a retrospective analysis of 50 gastrointestinal cancer patients treated with cetuximab in combination with either FOLFIRI or FOLFOX. One cohort of 15 patients received an in-house reactive skin protocol upon development of an exanthema. A second cohort of 15 patients received a skin prophylaxis starting with the first dose of cetuximab before clinical signs of toxicity. A third historic group o…

MaleCancer ResearchColorectal cancerAdministration TopicalAdministration OralCetuximabMinocyclineGastroenterologyPeritoneal NeoplasmPeritoneal NeoplasmsGastrointestinal NeoplasmsSkinHematologyintegumentary systemCetuximabTherapy reactiveMultimodal therapyVitamin K 1General MedicineMiddle AgedCombined Modality TherapyAnti-Bacterial AgentsSurvival RateTreatment OutcomeAppendiceal NeoplasmsOncologyColonic NeoplasmsAdenocarcinomaFemaleErratumQuinolizinesFluoroquinolonesmedicine.drugmedicine.medical_specialtyPrednisoloneEGFRDetergentsAntineoplastic AgentsAdenocarcinomaAntibodies Monoclonal HumanizedDisease-Free SurvivalMetronidazoleRashInternal medicineIntestinal NeoplasmsmedicineCombined Modality TherapyHumansSurvival rateAgedRetrospective StudiesOriginal PaperRectal Neoplasmsbusiness.industryRetrospective cohort studyAntibiotic ProphylaxisExanthemamedicine.diseaseDermatologydigestive system diseasesSurgerybusinessJournal of Cancer Research and Clinical Oncology
researchProduct

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

2018

Abstract Aim of the study The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting. Patients and methods Chemotherapy-naive patients received at least 8 cycles of FOLFIRINOX. The primary end-point was the 4-month disease control (4 m DC) rate. Tumour responses were centrally reviewed and assessed by computed tomography scan for metastases (Response Evaluation Criteria in Solid Tumours criteria) and magnetic resonance imaging for rectal tumorus. With a Simon 2-stage design and a targeted (H1) 4 m DC > 75%, 65 patients were enrolled from July 2012 to Februa…

MaleCancer ResearchLung NeoplasmsColorectal cancerFOLFIRINOXGastrointestinal DiseasesSynchronous metastasesLeucovorinKaplan-Meier EstimateInduction0302 clinical medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsRectal cancerINDUCTION TREATMENTFatigueResponse rate (survey)medicine.diagnostic_testLiver NeoplasmsRemission InductionMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingProgression-Free Survival3. Good healthOxaliplatinFOLFIRINOXTreatment OutcomeOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleRadiologyFluorouracilAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaIrinotecan03 medical and health sciencesmedicineHumansParesthesiaAgedPerformance statusbusiness.industryRectal NeoplasmsMagnetic resonance imagingmedicine.diseaseHematologic DiseasesConfidence intervalLocal controlbusinessTomography X-Ray ComputedFollow-Up Studies
researchProduct